# Briumvi (ublituximab)

Type: Product (TGTX)

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/briumvi-ublituximab
Canonical HTML page: https://getbiobrief.com/entity/briumvi-ublituximab

## Recent coverage (1 stories)

### Novartis, Roche Face 50% PBS Price Cut on MS Drugs as Briumvi Triggers Review
2026-07-15 21:43:22 · Sentiment: Negative · Impact: 7/10 · Sources: 11

A July 2026 Australian PBS review for Roche's Ocrevus and Novartis’s Kesimpta could reduce government reimbursement by up to 50%, triggered by reference pricing with new low-cost entrant Briumvi. Manufacturers risk margin erosion or market withdrawal.
Full story: https://getbiobrief.com/story/pbs-ms-review-pharma

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.